LIDAK PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE
LIDAK PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE LA JOLLA, Calif., Nov. 6 /PRNewswire/ -- Lidak Pharmaceuticals
(NASDAQ: LDAKU,LDAKA) announced today that its board of directors has relieved Fred A. Espinosa of his duties as the company's president and chief operating officer. There are no plans to replace Espinosa at this time and his duties will be divided among senior management.
Lidak Pharmaceuticals develops and commercializes innovative pharmaceutical and other significant products for the health care field. The company has entered into a 20-year technology license agreement with Medical Biology Institute ("MBI"), a nonprofit research organization, which gives Lidak exclusive marketing rights to products and technology developed by the institute. Through its license with MBI, Lidak is developing new therapeutic approaches for cancer, AIDS and autoimmune diseases. In addition, the company is developing its proprietary compound, Lidakol(TM), as a treatment for oral and genital herpes infections and other applications. -0- 11/6/91 /CONTACT: David H. Katz, M.D., chairman and CEO, 619-450-1538, or Michael H. Lorber, vice president and CFO, 619-558-0364, both of Lidak Pharmaceuticals; or Elizabeth Gard or Roger Pondel of Rifkind Pondel & Parsons, 310-207-9300, for Lidak Pharmaceuticals/ (LDAKU,LDAKA) CO: Lidak Pharmaceuticals, Medical Biology Institute ST: California IN: MTC SU: PER SE-EH -- LA012 -- 1538 11/06/91 08:32 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 6, 1991|
|Previous Article:||INTEGRATED HEALTH SERVICES ANNOUNCES MEDICAL SPECIALTY UNIT DEVELOPMENT PLAN FOR 1992; COMPANY TO INCREASE MSUs BY 60 PERCENT FOR 1992|
|Next Article:||FIRST CONSTITUTION GRANTS COMMON STOCK TO BANK EMPLOYEES|